Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study

Autor: Miranda T. Schram, Carroll A.B. Webers, M.M.J. van Greevenbroek, Casper G. Schalkwijk, Alphons J.H.M. Houben, Ronald M.A. Henry, C.J.H. van der Kallen, Coen D.A. Stehouwer, Nicolaas C. Schaper, Tos T. J. M. Berendschot, Koen D. Reesink, M. P. H. van de Waarenburg, Jean L.J.M. Scheijen, Nordin M J Hanssen
Přispěvatelé: Medical Image Analysis, Vascular Medicine, ACS - Diabetes & metabolism, ACS - Atherosclerosis & ischemic syndromes, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Dermatology, Interne Geneeskunde, RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Alg Onderzoek Interne Geneeskunde (9), RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, RS: MHeNs - R3 - Neuroscience, Oogheelkunde, MUMC+: MA UECM Oogartsen MUMC (9), MUMC+: University Eye Center Maastricht (3), MUMC+: *MA Oogheelkunde (3), RS: Carim - H07 Cardiovascular System Dynamics, Biomedische Technologie, RS: Carim - V02 Hypertension and target organ damage, RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: MA Endocrinologie (9), MUMC+: HVC Pieken Maastricht Studie (9), MUMC+: Centrum voor Chronische Zieken (3), MUMC+: MA Interne Geneeskunde (3)
Rok vydání: 2021
Předmět:
Male
endocrine system diseases
Endocrinology
Diabetes and Metabolism
030204 cardiovascular system & hematology
SDG 3 – Goede gezondheid en welzijn
Gastroenterology
0302 clinical medicine
Endocrinology
Chronic kidney disease
Prediabetes
ALL-CAUSE MORTALITY
Macrovascular disease
Diabetes
DICARBONYL STRESS
Fasting
General Medicine
Middle Aged
Pyruvaldehyde
Cardiovascular disease
Cardiovascular Diseases
Female
medicine.symptom
medicine.medical_specialty
END-PRODUCTS
Renal function
030209 endocrinology & metabolism
Prediabetic State
03 medical and health sciences
INFLAMMATION
SDG 3 - Good Health and Well-being
Internal medicine
Diabetes mellitus
Methylglyoxal
Internal Medicine
medicine
Humans
PLASMA-LEVELS
TYPE-1
Aged
INCIDENT CARDIOVASCULAR-DISEASE
ADVANCED GLYCATION ENDPRODUCTS
business.industry
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
Glucose Tolerance Test
medicine.disease
Blood pressure
ENDOTHELIAL DYSFUNCTION
Albuminuria
FOLLOW-UP
business
Kidney disease
Zdroj: Diabetes & Metabolism, 47(1):101148. Elsevier Masson s.r.l.
Diabetes & metabolism, 47(1):101148. Elsevier Masson
Diabetes & Metabolism, 47(1):101148. Elsevier Masson
ISSN: 1262-3636
Popis: Aims: Reactive dicarbonyl compounds, such as methylglyoxal (MGO), rise during an oral glucose tolerance test (OGTT), particularly in (pre)diabetes. Fasting MGO levels are associated with chronic kidney disease (CKD) and cardiovascular disease (CVD) in patients with poorly controlled type 2 diabetes mellitus (T2DM). Yet, whether fasting or post-OGTT plasma MGO levels are associated with vascular disease in people with (pre)diabetes is unknown. Methods: Subjects with normal glucose metabolism (n = 1796; age: 57.9 ± 8.2 years; 43.3% men), prediabetes (n = 478; age: 61.6 ± 7.6 years; 54.0% men) and T2DM (n = 669; age: 63.0 ± 7.5 years; 67.0% men) from the Maastricht Study underwent OGTTs. Plasma MGO levels were measured at baseline and 2 h after OGTT by mass spectrometry. Prior CVD was established via questionnaire. CKD was reflected by estimated glomerular filtration rate (eGFR) and albuminuria; retinopathy was assessed using retinal photographs. Data were analyzed using logistic regression adjusted for gender, age, smoking, systolic blood pressure, total-to-HDL cholesterol ratio, triglycerides, HbA 1c, BMI and medication use. Odd ratios (ORs) were expressed per standard deviation of LN-transformed MGO. Results: Fasting and post-OGTT MGO levels were associated with higher ORs for albuminuria ≥ 30 mg/24 h [fasting: 1.12 (95% CI: 0.97–1.29); post-OGTT: 1.19 (1.01–1.41)], eGFR < 60 mL/min/1.73 m 2 [fasting: 1.58 (95% CI: 1.38–1.82), post-OGTT: 1.57 (1.34–1.83)] and retinopathy [fasting: 1.59 (95% CI: 1.01–2.53), post-OGTT: 1.38 (0.77–2.48)]. No associations with prior CVD were found. Conclusion: Fasting and post-OGTT MGO levels were associated with microvascular disease, but not prior CVD. Thus, therapeutic strategies directed at lowering MGO levels may prevent microvascular disease.
Databáze: OpenAIRE
Externí odkaz: